High-Dose Statins for Dry AMD Drusen Regression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for age-related macular degeneration (AMD), particularly the dry form, lack effective solutions for regressing drusen, preventing atrophy of retinal pigmented epithelium and photoreceptors, and halting vision loss, despite the existence of treatments for the neovascular form.
Innovation Solution
Administering high-dose statins, such as atorvastatin, to patients with AMD to regress drusen, prevent atrophy, and improve visual acuity, with potential to convert from dry to wet AMD, combined with monitoring for efficacy and possible maintenance doses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If effective antiangiogenic treatments are used for neovascular AMD, then vision loss is prevented in wet AMD, but no effective treatment exists for the more prevalent dry form
Solution Approach 1:
The patent applies parameter changes by administering statins at high doses (e.g., atorvastatin 80mg daily) that exceed standard cardiovascular dosing. This high-dose parameter change enables the statin to achieve anti-inflammatory and drusen-regressing effects specific to dry AMD, rather than just cholesterol-lowering effects at standard doses
Solution Approach 2:
The patent demonstrates universality by showing that statins, originally developed for cardiovascular disease, can also effectively treat dry AMD when administered at high doses. This multi-functional application of a single drug class addresses both wet AMD (through antiangiogenic properties) and dry AMD (through anti-inflammatory and drusen-regressing properties)
2Manufacturing precision
If high-dose statins are administered to regress drusen, then drusen size reduces by at least 85%, but long-term administration is required
Solution Approach 1:
The patent applies preliminary action by initiating high-dose statin therapy early in the course of dry AMD, before significant atrophy of the retinal pigment epithelium or photoreceptors occurs. This early intervention prevents progression to advanced stages and maintains visual function while achieving drusen regression
Solution Approach 2:
The patent demonstrates continuity of useful action by requiring long-term, continuous administration of high-dose statins to maintain drusen regression and prevent atrophy. The continuous therapeutic action is necessary to sustain the anti-inflammatory effects and prevent recurrence or progression
3Reliability
If high-dose statins are used to prevent atrophy of retinal pigmented epithelium and photoreceptors, then vision loss is prevented, but visual acuity improvement requires significant gain of at least 3 to 12 letters
Solution Approach 1:
The patent applies feedback by using visual acuity measurements (letter gains of at least 3 to 12 letters) as quantitative indicators to monitor treatment response and adjust therapy. This feedback mechanism allows clinicians to assess whether the high-dose statin is effectively preventing atrophy and improving visual function
Data Source
AI summary
Methods of using a high-dose statin for treatment of AMD in a patient can be used to regress drusen and/or drusenoid pigment epithelial detachments (PEDs), to prevent atrophy of the RPE and/or one or more photoreceptors, to prevent vision loss and/or improve visual acuity, and/or to prevent progression from dry AMD to wet AMD.